- Home
- NCL vs TOVX Comparison
NCL vs TOVX Comparison
Compare NCL & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCL | TOVX |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.3M |
| IPO Year | 2023 | 2006 |
Fundamental Metrics
Financial Performance| Metric | NCL | TOVX |
|---|---|---|
| Price | $0.20 | $0.21 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.6M | 11.0M |
| Earning Date | 11-14-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,997,205.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.10 | $0.17 |
| 52 Week High | $12.16 | $2.03 |
Technical Indicators
Market Signals| Indicator | NCL | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 46.38 |
| Support Level | N/A | $0.19 |
| Resistance Level | N/A | $0.22 |
| Average True Range (ATR) | 0.00 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 33.50 |
Price Performance
Historical ComparisonAbout NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.